Cancer Research The Future of Cancer Research: Science and Patient Impact  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 33, 2362-2372, October 1, 1973]
© 1973 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Day, E. D.
Right arrow Articles by Bigner, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Day, E. D.
Right arrow Articles by Bigner, D. D.

Specificity, Cross-reactivity, and Affinity of 125I-Labeled Antiglioma Antibodies for Monolayers of Cultured Glioma Cells1

Eugene D. Day and Darell D. Bigner

Departments of Microbiology-Immunology [E. D. D., D. D. B.], Pathology [D. D. B.], and Surgery [E. D. D., D. D. B.], Duke University Medical Center, Durham, North Carolina 27710

The sequential method of adsorption analysis was applied to antiglioma radioantibodies adsorbed by intact monolayer cultures of the C6 rat astrocytoma cell line. A noncentrifugal technique was devised to permit transfer of radioantibody solutions from one culture to the next in a sequence and to effect removal of unbound radioglobulins. Primary binding of 125I-labeled antibody immunoglobulin G (IgG) was readily measured in a particularly sensitive and reproducible manner over and above control IgG. With proportions varying from one serum to the next, several individual antiglioma radioantibody preparations, after preadsorption three times with rat liver, still retained cross-reactivity for fibroblast cultures and, after preadsorption three times with fibroblasts, still retained selective reactivity for glioma cells. When adsorbed with glioma cells first, the bulk of all binding activity remained with the glial cells. When unlabeled antibody IgG in varying amounts was mixed with fixed quantities of labeled antibody IgG and glioma cells, an equivalence point was established by competitive binding curves and, independently, by microscopic examination of the monolayer-antibody complexes after light trypsinization: cell clumps in excess antibody, free cells otherwise. parameters of IgG binding in one antibody-cell combination were Ka = 2.1 x 106 M-1; a = 0.75; and s = 6.9 x 107 antigenic sites/cells. When two cloned sublines of the S-77 line of the C6 astrocytoma were used sequentially along with fibroblasts to adsorb a radioantibody preparation from one particular anti-S-77 antiserum in nine steps, four different antigenic moieties were clearly distinguished: a cross-reaction between fibroblasts and glioma cells; a cross-reaction between the two sublines that was not shared by fibroblasts; and a distinctive reaction in each of the two sublines that was not shared by the other subline or by fibroblasts.

1 This work was supported by Grants CA-14651 and CA-11898 from the National Cancer Institute and by Grant NS-10237 from the National Institute of Neurologic Diseases and Stroke, NIH, Bethesda, Md.

Received 4/ 2/73. Accepted 6/20/73.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1973 by the American Association for Cancer Research.